<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814175</url>
  </required_header>
  <id_info>
    <org_study_id>M14-496</org_study_id>
    <secondary_id>2016-000191-21</secondary_id>
    <nct_id>NCT02814175</nct_id>
  </id_info>
  <brief_title>A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)</brief_title>
  <acronym>CONTROL</acronym>
  <official_title>A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An interventional Phase 4 open-label, randomized, controlled, parallel-group, multi-country
      study in subjects with psoriatic arthritis (PsA) consisting of 2 parts: Part 1 is designed to
      compare the achievement of minimal disease activity (MDA) between subjects randomized to
      either adalimumab in combination with methotrexate (MTX) or MTX alone escalated to the
      highest recommended or tolerable dose; Part 2 is to evaluate the maintenance or achievement
      of MDA on four different treatment regimens using adalimumab and/or MTX, with subject
      allocation based on the initial randomized treatment and achievement of MDA in Part 1, and
      with rescue treatment option.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2016</start_date>
  <completion_date type="Anticipated">August 5, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects achieving minimal disease activity</measure>
    <time_frame>At week 16</time_frame>
    <description>Minimal disease activity will be determined by tender and swollen joint counts, PASI or body surface area (BSA), Patient's assessment of pain visual analogue scale, Patient's global assessment of disease activity VAS, HAQ-DI, and tender entheseal points assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in DLQI score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>DLQI is a measure of subject's quality of life related to skin disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tender dactylitic digit count from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>Hands and feet bilaterally will be assessed for the presence/absence of dactylitis and associated tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS28-CRP score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>DAS28 is a weighted measure of disease activity originally developed for RA, but is also used in PsA clinical trials. DAS28 includes tender and swollen joint counts, Patient's global assessment of disease activity, Patient's global assessment of arthritis and acute phase reactant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PsAID score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>PsAID is a validated patient self-reported tool to assess the impact of PsA on the patient's life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving ACR 20/50/70 response</measure>
    <time_frame>At Week 16</time_frame>
    <description>ACR 20/50/70 response rate will be determined based on 20%, 50%, and 70% or greater improvement of Tender Joint Count and Swollen Joint Counts and greater than or equal to 3 of the 5 measures of Patient's assessment of pain, Patient's global assessment of disease activity, Physician's global assessment of disease activity, HAQ-DI, and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leeds Enthesitis Index (LEI) from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>LEI is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in minimal disease activity in Part 2 of the study</measure>
    <time_frame>At week 32</time_frame>
    <description>Minimal disease activity will be determined by tender and swollen joint counts, PASI or body surface area (BSA), Patient's assessment of pain visual analogue scale, Patient's global assessment of disease activity VAS, HAQ-DI, and tender entheseal points assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PASDAS from baseline</measure>
    <time_frame>Measured from Day 1 to week 16</time_frame>
    <description>Psoriatic Arthritis Disease Activity Score is a weighted disease activity measure developed specifically for psoriatic arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>SF-36 is a generic measure to assess patient's general health and well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HAQ-DI score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>The HAQ-DI is a standardized measure of physical function in arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving PASI 75/90/100 response among subjects with BSA greater than or equal to 3%.</measure>
    <time_frame>At Week 16</time_frame>
    <description>Denotes greater than or equal to 75%/90%/100% improvement in PASI score. PASI provides a quantitative assessment of psoriasis lesional burden based on the amount of body surface area involved and the degree of severity of erythema, induration, and scale, weighted by body part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAPSA score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>DAPSA is a psoriatic arthritis disease activity measure, calculated by summing swollen and tender joint counts, Patient's assessment of pain, Patients global assessment of disease activity, and CRP.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">119</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Arm 2/Part 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTX highest recommended or tolerable dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1/Part 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab + MTX low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3/Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTX highest recommended or tolerable dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4/Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab +MTX highest recommended or tolerable dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rescue Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab and/or MTX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2/Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab + MTX low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1/Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate (MTX)</intervention_name>
    <arm_group_label>Arm 1/Part 1</arm_group_label>
    <arm_group_label>Arm 2/Part 1</arm_group_label>
    <arm_group_label>Arm 2/Part 2</arm_group_label>
    <arm_group_label>Arm 3/Part 2</arm_group_label>
    <arm_group_label>Arm 4/Part 2</arm_group_label>
    <arm_group_label>Rescue Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <arm_group_label>Arm 1/Part 1</arm_group_label>
    <arm_group_label>Arm 1/Part 2</arm_group_label>
    <arm_group_label>Arm 2/Part 2</arm_group_label>
    <arm_group_label>Arm 4/Part 2</arm_group_label>
    <arm_group_label>Rescue Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. PsA diagnosis established at least 4 weeks prior to the date of the Screening visit
             and confirmed by ClASsification of Psoriatic Arthritis (CASPAR) criteria

          2. Not in MDA at the time of screening

          3. Has 3 or more tender and 3 or more swollen joints

          4. Treated with methotrexate 15 mg (weekly) for at least 4 weeks

        Exclusion Criteria:

          1. Contraindications to adalimumab therapy and/or known hypersensitivity to adalimumab or
             its excipients

          2. History of methotrexate intolerance/toxicity

          3. Medical conditions(s) precluding methotrexate dose increase above 15 mg

          4. Had prior exposure to any tumor necrosis factor (TNF) inhibitor, other mechanism of
             action biologic DMARD (bDMARD) or any systemic biologic agent in general
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AZ Arthritis &amp; Rheum Research</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LeJenue Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Deerbrook Medical Associates</name>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Gr</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shores Rheumatology, PC</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Health Care</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Altoona Ctr Clinical Res</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Virginia Research Inst</name>
      <address>
        <city>South Charleston</city>
        <state>West Virginia</state>
        <zip>25309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Optimus Clinical Research Pty.</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BJC Health</name>
      <address>
        <city>Paramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>Sao Paulo</state>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MHAT Trimontsium</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diag Consult Ctr 17 Sofia EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1505</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alberta Rheumatology Research Assoc</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5M 0H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Percuro Clinical Research, Ltd</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A IM3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Clare's Mercy Hospital</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 5B8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Waterside Clinic</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adachi Medicine Prof. Corp</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ctr. de Rheum de l'est du QC</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 5T1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Riesgo de Fractura S.A - CAYRE</name>
      <address>
        <city>Bogota</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Vicente Fundacion</name>
      <address>
        <city>Medellin</city>
        <zip>050034</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nuselská poliklinika, Revmatologie</name>
      <address>
        <city>Prague 4</city>
        <state>Praha 4</state>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jihlava Hospital</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wurttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Hosp Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CIRI GmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamburger Rheuma I</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università di Catanzaro &quot;Magna Graecia&quot;</name>
      <address>
        <city>Catanzaro</city>
        <state>Calabria</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinic</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MCBK SC</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <state>Mazowieckie</state>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne AMED</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>01-518</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SANUS Szpital Specjalistyczny</name>
      <address>
        <city>Stalowa Wola</city>
        <state>Podkarpackie</state>
        <zip>37-450</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinicMed Badurski i wspolnicy SJ</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Ramon L. Ortega-Colon, MD</name>
      <address>
        <city>Carolina</city>
        <zip>00983</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamad Hospital</name>
      <address>
        <city>Doha</city>
        <state>Ad Dawhah</state>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Germans Trias I</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina S</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Manises</name>
      <address>
        <city>Manises</city>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Corporac Sanitaria Parc Taul</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Viladecans</name>
      <address>
        <city>Viladecans</city>
        <zip>8840</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal National Hosp for Rheuma</name>
      <address>
        <city>Bath</city>
        <zip>BA1 1RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Altnagelvin Area Hospital</name>
      <address>
        <city>Londonderry</city>
        <zip>BT47 6SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Manchester University</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lancashire Care NHS Foundation</name>
      <address>
        <city>Preston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Qatar</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriatic Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

